Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ermine what, if any, impact these data might have on other ongoing clinical trials evaluating the safety and efficacy of Nexavar.

"Bayer and Onyx are disappointed with these results, in particular, for patients who are suffering from this deadly disease," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare.  "We are confident in our clinical trial program exploring Nexavar's potential in a variety of tumor types, including lung cancer.  Based on encouraging data from a recently presented prospective biomarker trial and Phase 2 signal-generating lung cancer studies, we believe it's critical to continue our evaluation of Nexavar in combination with targeted agents and as a monotherapy in later lines of treatment in lung cancer patients."

Nexavar is being evaluated by the companies and individual investigators in a variety of treatment settings for patients with non-small cell lung cancer, including a Phase 3 monotherapy study in the third- and fourth-line setting and Phase 2 studies in combination with other therapies in the second-line setting.

NExUS Trial Design

This Phase 3, randomized, double-blind, placebo-controlled study evaluated Nexavar (sorafenib) tablets in combination with the chemotherapeutic agents, gemcitabine and cisplatin, in treatment-naive non-small cell lung cancer patients.  The primary endpoint was overall survival, and secondary endpoints included progression-free survival, tumor response and safety.  Patients were randomized to receive 400 mg of oral Nexavar or matching placebo twice daily, in addition to gemcitabine and cisplatin for up to six cycles.  Subsequently, patients continued in a maintenance phase where Nexavar or placebo was administered as a single agent.  The study enrolled approximately 90
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... -- The global high content screening market is a ... Obsolescence, wherein technologies as well as their adoption by ... as well as academic and government institutes are increasingly ... research tool in drug discovery. The high content screening ... content screening market. In high content screening, the accuracy ...
(Date:10/1/2014)... 1, 2014   Plexus Information Systems, Inc. ... Information Management Systems (AIMS), announced a partnership with ... wholly owned subsidiary of Quality Systems, Inc. and ... connectivity solutions.  Logo - ... This partnership extends the NextGen Healthcare ...
(Date:10/1/2014)... and NEW YORK , October 1, ... Research Organization (CRO) and service provider for the medical industries, announced ... of offices in New York City . genae ... City is strategically centered in one of the highest ... Coast", said Philippe Kassab , President at genae Americas. "The ...
Breaking Medicine Technology:High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3genae Opens Offices in New York City 2
... LOUIS, Feb. 23, 2011 Stereotaxis, Inc. (Nasdaq: ... Magnetic Navigation System in a renal artery ablation procedure for ... medication.  This procedure was performed by Petr Neuzil, MD, PhD, ... at the Na Homolce Hospital in Prague, Czech Republic.   ...
... Reportlinker.com announces that a new market research report ... Global Orthopedic Prosthetics Industry ... the worldwide markets for Orthopedic Prosthetics in US$ ... Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis, ...
Cached Medicine Technology:Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension 2Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension 3Stereotaxis Announces First Worldwide Use of Remote Magnetic Navigation for Renal Ablation to Treat Hypertension 4Reportlinker Adds Global Orthopedic Prosthetics Industry 2
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
(Date:10/1/2014)... 01, 2014 Farmington Company today ... redefined mission and visual identity helping brokers, consultants ... with them to create greater benefit communication synergies. ... focuses on empowering customers to better leverage Farmington ... crown jewel of the rebrand is the refreshed ...
(Date:10/1/2014)... N.C. A new genetic finding from Duke Medicine ... anxiety and depression might also be hard-wired to gain ... and heart disease. , An estimated 13 percent of ... genetic susceptibility, and knowing this could help them reduce ... diet, exercise and stress management. , "Genetic susceptibility, psychosocial ...
(Date:10/1/2014)... October 01, 2014 Between 23 million ... the U.S., according to figures from the National Institutes ... Association (AARDA), and many of them have something else ... having undiagnosed celiac disease. Gluten Free Therapeutics, makers ... of undiagnosed celiac disease by publishing a series of ...
(Date:10/1/2014)... Jersey City, NJ (PRWEB) October 01, 2014 ... sticking with their intentions to lose weight and their dieting ... in unhealthy, fatty foods. Including hormone diet treatments ... not only allows patients to see fast and effective weight ... diet and begin forming healthy habits to maintain their weight ...
Breaking Medicine News(10 mins):Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... ... Saudi Arabia, SOMERSET, N.J., ... subsidiary AWT International, Inc.,has opened new sales offices in Saudi Arabia. ... U.S. healthcare industry. The Company has hired 2 highly experienced ...
... one source of frustration, study finds , TUESDAY, Oct. 9 ... U.S. Hispanics, ability to get good health care, a new ... have difficulty navigating the health care system, say researchers reporting ... , In this study, a team led by Robert Weech-Maldonado, ...
... Oct. 8, 2007 Two UT Southwestern Medical Center ... neuroscientist have been elected to the Institute of ... Sciences. , Dr. Luis Parada, professor and chairman ... chairman of neuroscience, were among 65 new national members ...
... financial and clinical ... -- Announces name change from ... Today, UPCARE Technology, Inc.,unveiled its new UPCARE(R) E2E lab performance ... of its parent company, Marquette,General Health System (MGHS). The company ...
... Oct. 9 Many Americans are obsessed with,staying in ... being,mentally fit. More Americans are becoming aware of the ... knowledge, intelligence, and quick,wits are rewarded. Being mentally fit ... train your brain have been lacking,until recently. A ...
... Award-winning Internet job board establishes new social and professional ... and health care community, LAKE WORTH, Fla., Oct. 9 ... care field, your job is extremely demanding, perhaps,even all-consuming. Finding ... tough, as is catching up on the latest industry news ...
Cached Medicine News:Health News:AWT, Inc. Continues Rapid Expansion in Middle East 2Health News:AWT, Inc. Continues Rapid Expansion in Middle East 3Health News:Many U.S. Hispanics Struggle With Health Care System 2Health News:2 UT Southwestern researchers elected to National Academy of Sciences' Institute of Medicine 2Health News:2 UT Southwestern researchers elected to National Academy of Sciences' Institute of Medicine 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4Health News:Online Game from BrainGrade Can Raise Brain I.Q. 2Health News:Absolutely Health Care Launches MedicalMingle.com 2
For injecting anesthetics into the muscle cone. 23G x 1 1/2 in (.60 x 38mm)...
... This all digital single plane C-arm ... unprecedented cardiac imaging performance and an expansive ... from cardiac angiography to ECG triggered. ... Flat Detector technology,State of the art dynamic ...
... is a complete vestibular diagnostic system ... movements collected via electrodes. Its Windows-based ... use. Saccade, tracking and Slow Phase ... is facilitated by graphic comparison of ...
For diagnostic and operative treatment of hand and wrist bones. The use of this distraction device allows fracture reduction or widening of the space between bones....
Medicine Products: